Juno Therapeutics, Inc. a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle.
The new headquarters brings together Juno’s Seattle employees – previously spread among three locations – enabling the company’s scientists, researchers, technical professionals and administrative staff to work collaboratively in a state-of-the-art facility. The company’s move signifies its investment in the science that is critical to driving developments in cell therapy.
“At Juno, our single focus is delivering on the promise of cell therapy. This is an exciting new frontier in medicine with the potential to change the way we treat cancer,” said Hans Bishop, Juno’s President and Chief Executive Officer.
“Our new headquarters and research facility underscore our investment in this future and our commitment to deliver better treatments to our patients.”
Dan Symes, a patient diagnosed with aggressive B-cell non-Hodgkin lymphoma that is now in remission after treatment with Juno’s JCAR017 product candidate, was a featured guest at the building opening. “My specific type of cancer did not respond to other traditional cancer therapies. Our family felt like we had run out of options,” said Mr. Symes. “Now, I am in remission and have gone back to work. I’m so thankful for Juno’s commitment to immunotherapy and the hope that it offers patients battling cancer. I urge Juno’s people to continue their important work so they can help more people like me.”
Juno’s move to the headquarters and research facility comes during a momentous period for both the field of cell therapy and the company. The U.S. Food and Drug Administration approved the first chimeric antigen receptor (CAR) T therapy earlier this month, and Juno posted very encouraging data with JCAR017 in June. Juno believes data from the JCAR017 trial may support FDA approval for the treatment of aggressive non-Hodgkin Lymphoma as soon as 2018. Juno also possesses a deep pipeline of other product candidates focused on a number of cancers.
About Juno Therapeutics
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno’s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans, the potential of cell therapy and immunotherapy, the timing of regulatory approval, and the promise of Juno’s product candidate pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance.
These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno’s product development activities and clinical trials; Juno’s ability to obtain regulatory approval for and to commercialize its product candidates; Juno’s ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno’s competitors with respect to competing treatments and technologies; Juno’s dependence on third-party collaborators and other contractors in Juno’s research and development activities, including for the conduct of clinical trials and the manufacture of Juno’s product candidates; Juno’s ability to attract and retain key scientific, quality control/assurance, manufacturing or management personnel; Juno’s dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno’s business in general, see the information Juno has included it its periodic reports and other documents filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.
View source version on businesswire.com:
Source: Juno Therapeutics, Inc.
Juno Therapeutics, Inc.
Nicole Keith, 206-566-5521
Christopher Williams, 206-566-5660